Methotrexate

Title	Average Rating
Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs.	90.00%
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor acti	90.00%
The anti-angiogenic basis of metronomic chemotherapy.	85.00%
Different metronomic treatment schedules	80.00%
Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer	70.00%
Low-dose methotrexate and cyclophosphamide in recurrent ovarian cancer.	60.00%
Oral methotrexate for recurrent brain tumors in children: a Pediatric Oncology Group study.	60.00%
Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy	50.00%
Outpatient administration of high-dose methotrexate for osteosarcoma treatment in Brazil.	30.00%
A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer.

Languages